Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pouchitis
Conditions
Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Trial Timeline
Aug 12, 2025 → Apr 1, 2027
NCT ID
NCT06864403About Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)
Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC) is a approved stage product being developed by Eli Lilly for Pouchitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864403. Target conditions include Pouchitis, Pouches, Ileoanal, Pouch, Ileal.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06864403 | Approved | Recruiting |
Competing Products
3 competing products in Pouchitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Liraglutide Pen Injector + Placebo Pen Injector | Novo Nordisk | Phase 2 | 51 |
| etrasimod + Placebo | Pfizer | Phase 2 | 51 |
| Rifaximin 550 MG Oral Tablet [XIFAXAN] | Bausch Health | Approved | 80 |